Docoh
Loading...

BCRX Biocryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.

Company profile

Ticker
BCRX
Exchange
CEO
Jon Stonehouse
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
621413174

BCRX stock data

(
)

Calendar

7 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 226.9M 226.9M 226.9M 226.9M 226.9M 226.9M
Cash burn (monthly) 15.08M (positive/no burn) 17.13M 15.43M 20.34M 14.58M
Cash used (since last report) 61.77M n/a 70.17M 63.22M 83.33M 59.74M
Cash remaining 165.13M n/a 156.73M 163.68M 143.57M 167.16M
Runway (months of cash) 11.0 n/a 9.2 10.6 7.1 11.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Jul 21 Milano Vincent NQSO Common Stock Grant Aquire A No No 17.25 66,667 1.15M 66,667
15 Jul 21 Abercrombie George B Common Stock Sell Dispose S No Yes 15.69 5,000 78.45K 3,000
15 Jul 21 Abercrombie George B Common Stock Option exercise Aquire M No Yes 2.63 5,000 13.15K 8,000
15 Jul 21 Abercrombie George B NQSO Common Stock Option exercise Dispose M No Yes 2.63 5,000 13.15K 5,000
10 Jun 21 Nancy J Hutson Common Stock Sell Dispose S No Yes 16.86 23,333 393.39K 65,073
10 Jun 21 Nancy J Hutson Common Stock Option exercise Aquire M No Yes 3.32 15,000 49.8K 88,406
10 Jun 21 Nancy J Hutson Common Stock Option exercise Aquire M No Yes 2.85 8,333 23.75K 73,406
10 Jun 21 Nancy J Hutson Automatic Stock Option Grant Common Stock Option exercise Dispose M No Yes 3.32 15,000 49.8K 0
10 Jun 21 Nancy J Hutson NQSO Common Stock Option exercise Dispose M No Yes 2.85 8,333 23.75K 0
28 May 21 Steve Aselage Common Stock Grant Aquire A No No 15.77 634 10K 32,130

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

58.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 191 177 +7.9%
Opened positions 47 40 +17.5%
Closed positions 33 16 +106.3%
Increased positions 55 56 -1.8%
Reduced positions 69 56 +23.2%
13F shares
Current Prev Q Change
Total value 1.37B 999.53M +37.3%
Total shares 104.51M 120.63M -13.4%
Total puts 1.94M 1.15M +69.4%
Total calls 2.84M 1.26M +125.7%
Total put/call ratio 0.7 0.9 -24.9%
Largest owners
Shares Value Change
BLK Blackrock 16.24M $165.18M -0.1%
Baker Bros. Advisors 12.71M $129.27M +0.1%
Vanguard 9.7M $98.65M -16.4%
Sarissa Capital Management 7.64M $77.68M -6.6%
STT State Street 7.31M $74.33M -33.9%
HealthCor Management 4.89M $49.7M NEW
Artisan Partners Limited Partnership 3.03M $30.77M NEW
Geode Capital Management 2.99M $30.41M +12.6%
Deerfield Management 2.61M $26.5M -55.4%
Nuveen Asset Management 2.5M $25.47M +59.3%
Largest transactions
Shares Bought/sold Change
Citadel Advisors 807.61K -5.69M -87.6%
HealthCor Management 4.89M +4.89M NEW
STT State Street 7.31M -3.75M -33.9%
Point72 Asset Management 0 -3.23M EXIT
Deerfield Management 2.61M -3.23M -55.4%
Artisan Partners Limited Partnership 3.03M +3.03M NEW
Marshall Wace North America 865.54K -1.93M -69.1%
Vanguard 9.7M -1.9M -16.4%
GS Goldman Sachs 2.17M +1.87M +614.9%
IVZ Invesco 1.43M +1.4M +3766.7%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: activin, adjudication, adolescent, Athyrium, Autorisation, capped, Cautionary, center, Codification, constrained, contemporaneously, conversion, count, covenant, Cure, defective, depict, drawn, EC, extinguishment, focusing, France, freight, French, front, Germany, heading, hereof, impute, imputed, inclusive, indeterminate, intake, Intermediate, Ireland, leaseback, lessee, linear, mandated, mix, NaN, negligent, NHI, obligor, opsonization, payoff, PERAMIFLU, pharmacy, PIK, prepaid, prepay, principle, prophylactic, RABIVAB, reader, refer, reference, repurchase, reticulocyte, RPI, runway, Secretary, Simplifying, specialty, step, stoppage, suggested, sum, symptomatic, Temporaire, thereon, timeframe, turn, unamortized, unaudited, uncomplicated, unintentional, unrelated, unsold, voluntary
Removed: accept, actively, alleviate, ALPIVAB, amending, anticipation, arbitrator, ascending, Asia, Australasia, biopharmaceutical, Brazil, Brazilian, broader, Callaghan, Canadian, Carbohydrate, caution, CDC, centralized, characterize, clarified, closed, collected, combination, Commencing, commercialized, compound, concept, confirmed, constitute, convey, depository, designation, discharge, dissolve, dosed, doubt, eculizumab, effectuate, endpoint, exceeded, experimental, expressed, fashion, Ferrier, floating, forecast, formal, formed, fulfilling, Goodwill, hemorrhagic, hosting, impacting, IND, indirectly, inhibition, Innovation, Innovative, investigational, kallikrein, largest, line, liquidate, liquidating, MAA, MAD, mark, materialize, MDCP, modify, mortality, move, Nacional, nation, novation, observed, opened, oversee, PCR, PD, peak, pending, pharmacodynamic, pharmacokinetic, PK, post, posted, presidential, projecting, Promising, promoting, proof, prospect, qualitative, randomized, ravulizumab, reaction, redeemable, redeemed, redemption, refinanced, remdesivir, repeal, replaced, respiratory, restating, revise, ROFN, rulemaking, Sakigake, seasonality, stream, substitution, Subtopic, supportable, threshold, Trump, ulodesine, unanticipated, unchanged, uncured, undetectable, unfold, User, validated, Victoria, volume, VUW, Wellington, wholly